Merck introduced optimistic top-line outcomes from a pivotal part 3 stellar trial for the remedy of adults with pulmonary arterial hypertension (PAH).

October 10, 2022 at 6:45am ET Sotarecept demonstrated important enchancment in train capability and key secondary end result measures in comparison with placebo when added to background remedy RAHWAY, NJ–(BUSINESS WIRE)–Merck (NYSE:MRK), often known as MSD outdoors america and Canada, at this time handed optimistic from the pivotal Part 3 Stellar trial evaluating the protection … Read more